According to this new research report, the Global Alzheimer Drugs Market was valued at USD 6537.0 Million in the year 2021.
Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions.
In addition, the market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. Telehealth can be defined as the remote delivery of clinical as well as non-clinical services through tele and digital communication technologies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab and Solanezumab. The development of these drugs is anticipated to propel market growth in the coming years.
Moreover, the increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market. Also, rising R&D activities by pharmaceutical companies and research institutes for Alzheimer’s effective therapy is expected to boost the global Alzheimer’s drugs market.
Scope of the Report
- The report presents the analysis of the Alzheimer Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027
- The report analyses the Alzheimer Drugs Market by value (USD Million)
- The report analyses the Alzheimer Drugs Market by Drug Class (Cholinergic, Memantine, Combined drug, others).
- The report analyses the Alzheimer Drugs Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- The Global Alzheimer Drugs Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA).
- The Global Alzheimer Drugs Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India and Australia)
- The attractiveness of the market has been presented by region, by Drug Class and By Distribution Channel.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
- The companies analysed in the report include AbbVie Inc., F. Hoffman-La Roche, Ltd., Novartis AG, Biogen, Pfizer Inc., Eli Lilli and Company, Takeda Pharmaceutical Company Limited, Novo Nordisk, Daiichi Sankyo Company Ltd., Eisai Co. Ltd, NervGen Pharma.
Key Target Audience:
- Alzheimer Drugs Manufacturers
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Table of Contents
1. Report Scope and Methodology1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Alzheimer Drugs Market: Product Outlook
4. Global Alzheimer Drugs Market: Sizing and Forecast
4.1 Global Alzheimer Drugs Market Size, By Value, Year 2017-2027
4.2 Impact of COVID-19 on Global Alzheimer Drugs Market
5. Global Alzheimer Drugs Market Segmentation -By Drug Class, By Distribution Channel
5.1 Competitive Scenario of Global Alzheimer Drugs Market: By Drug Class
5.1.1 Cholinergic -Market Size and Forecast (2017-2027)
5.1.2 Memantine -Market Size and Forecast (2017-2027)
5.1.3 Combined drug -Market Size and Forecast (2017-2027)
5.1.4 Others -Market Size and Forecast (2017-2027)
5.3 Competitive Scenario of Global Alzheimer Drugs Market: By Distribution Channel
5.3.1 Hospitals Pharmacy-Market Size and Forecast (2017-2027)
5.3.2 Retail Pharmacy - Market Size and Forecast (2017-2027)
5.3.3 Online Pharmacy -Market Size and Forecast (2017-2027)
6. Global Alzheimer Drugs Market: Regional Analysis
6.1 Competitive Scenario of Global Alzheimer Drugs Market : By Region
7. North America Alzheimer Drugs Market: An Analysis (2017-2027)
7.1 North America Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
7.2 North America Alzheimer Drugs Market -Prominent Companies
7.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
7.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.5 North America Alzheimer Drugs Market: Country Analysis
7.6 Market Opportunity Chart of North America Alzheimer Drugs Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Alzheimer Drugs Market: By Country
7.8 United States Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
7.9 United States Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
7.10 Canada Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
7.11 Canada Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8. Europe Alzheimer Drugs Market: An Analysis (2017-2027)
8.1 Europe Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
8.2 Europe Alzheimer Drugs Market -Prominent Companies
8.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
8.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.5 Europe Alzheimer Drugs Market: Country Analysis
8.6 Market Opportunity Chart of Europe Alzheimer Drugs Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Alzheimer Drugs Market: By Country
8.8 Germany Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.9 Germany Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.10 United Kingdom Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.11 United Kingdom Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.12 France Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.13 France Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
8.14 Italy Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
8.15 Italy Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9. Asia Pacific Alzheimer Drugs Market: An Analysis (2017-2027)
9.1 Asia Pacific Alzheimer Drugs Market : Size and Forecast (2017-2027), By Value
9.2 Asia Pacific Alzheimer Drugs Market -Prominent Companies
9.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
9.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.5 Asia Pacific Alzheimer Drugs Market: Country Analysis
9.6 Market Opportunity Chart Asia Pacific Alzheimer Drugs Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Alzheimer Drugs Market: By Country
9.8 China Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.9 China Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.10 Japan Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.11 Japan Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.12 India Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.13 India Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.14 Australia Alzheimer Drugs Market: Size and Forecast (2017-2027), By Value
9.15 Australia Alzheimer Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
10. Global Alzheimer Drugs Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Drug Class, 2026
11.2 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Alzheimer Drugs Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Alzheimer Drugs Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 AbbVie Inc.,
13.2 F. Hoffman-La Roche, Ltd.
13.3 Novartis AG
13.4 Biogen
13.5 Pfizer Inc.,
13.6 Eli Lilli and Company
13.7 Takeda Pharmaceutical Company Limited
13.8 Novo Nordisk
13.9 Daiichi Sankyo Company Ltd.
13.10 Eisai Co. Ltd
13.11 NervGen Pharma
14. About the Publisher
List of Figures
- Global Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Global Number of People With Dementia, in Million, in Low, Middle and High In come Countries, 2015-2020
- World’s leading causes of death (in millions), 2019
- World Population 65 Years & Above (% of Total), 2015-2019
- Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
- Global Alzheimer - Number of Drugs by Phase, In Percentage, 2020
- Global Alzheimer Drugs Market - By Drug Class Market Share, 2021 & 2027
- Global Alzheimer Drugs Market - By Cholinergic, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Memantine, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Combined drug, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Others, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Distribution Channel Market Share, 2021 & 2027
- Global Alzheimer Drugs Market - By Hospital Pharmacy, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Retail Pharmacy, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Online Pharmacy, By Value (USD Million), 2017-2027
- Global Alzheimer Drugs Market - By Region Market Share, 2021 & 2027
- North America Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- North America Population ages 65 and above (% of total Population), 2016-2020
- United States lifetime risk for Alzheimer's dementia at age 45 and 65 for both Men and Women, 2020 (In %age)
- North America Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- North America Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Market Opportunity Chart of North America Alzheimer Drugs Market - By Country, By Value (Year 2017-2027)
- North America Alzheimer Drugs Market - By Country Market Share, 2021 & 2027
- United States Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- United State Number of People Living with Alzheimer’s Disease, By Age (In Millions), 2020
- Alzheimer's disease mortality rate in the United States from 2015 to 2019, (per 100,000 population)
- United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- United States Percentage Changes in Selected Causes of Death (All Ages) Between 2000 and 2019, (In %age)
- United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
- United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- United States Population aged 65 and above (% of total Population), 2016-2020
- United State Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- United State Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Canada Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- Canada Death Rate for Alzheimer Disease (Per 100,000 Population), 2015-2019
- Canada Population aged 65 and above (% of total Population), 2016-2020
- Canada Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Canada Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Europe Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- European Countries Population ages 65 and above (% of total Population), 2020
- Europe Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Europe Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Figure 48: Market Opportunity Chart of Europe Alzheimer Drugs Market - By Country, By Value (Year 2017-2027)
- Europe Alzheimer Drugs Market - By Country Market Share, 2020 & 2026
- Germany Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
- Germany Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Germany Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- United Kingdom Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- United Kingdom Population ages 65 and above (% of total Population), 2016-20
- United Kingdom Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- United Kingdom Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- France Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- France Population ages 65 and above (% of total Population), 2016-20
- France Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- France Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Italy Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- Italy Population ages 65 and above (% of total Population), 2016-20
- Italy Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Italy Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Asia Pacific Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
- Asia Pacific Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Asia Pacific Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Market Opportunity Chart of APAC Alzheimer Drugs Market - By Country, By Value (Year-2026)
- APAC Alzheimer Drugs Market - By Country Market Share, 2021 & 2027
- China Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
- China Population ages 65 and above (% of total Population), 2016-20
- China Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- China Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Japan Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
- Japan Alzheimer’s Drugs company market share (%), 2020
- Japan Alzheimer’s Drugs company market share (%), 2020
- Japan Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Japan Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- India Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
- e-pharmacy market in India (USD million)
- India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
- India Population ages 65 and above (% of total Population), 2016-20
- India Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- India Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Australia Alzheimer Drugs Market Size, By Value, 2017-2027 (USD Million)
- Australia current health expenditure (% of GDP), (2014-2018)
- Australia population aged 65 and above (% of total population), 2017-2021
- Australia urban population (% of total population), 2017-2021
- Australia Alzheimer Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
- Australia Alzheimer Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
- Market Attractiveness Chart of Global Alzheimer Drugs Market - By Drug Class (Year-2017-2027)
- Market Attractiveness Chart of Global Alzheimer Drugs Market - By Distribution Channel (Year 2017-2027)
- Market Attractiveness Chart of Global Alzheimer Drugs Market - By Region (Year 2017-2027)
- Global Alzheimer’s Drugs company market share (%), 2020
- AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
- AbbVie Inc. Net Income (USD Million), 2016-2020
- AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
- AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
- F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
- F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
- F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
- F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
- Novartis Annual Sales Revenue (USD Million), 2016-2020
- Novartis Annual Net Income/Loss (USD Million), 2016-2020
- Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
- Novartis Sales Revenue Split, By Geography Segment (%), FY2020
- Biogen Sales Revenues, 2016-2020 (USD Million)
- Biogen Net Profit, 2016-2020 (USD Million)
- Biogen, By Business Segment (%), FY2020
- Biogen, By Geographical Segment (%), FY2020
- Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
- Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
- Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
- Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
- Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
- Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
- Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
- Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
- Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
- Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
- Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
- Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
- Novo Nordisk Net Profit, 2016-2020 (USD Million)
- Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
- Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
- Daiichi Sankyo Company Ltd. Revenue, 2020-2021 (In USD Million)
- Daiichi Sankyo Company Ltd. Sales Revenue Split, By Business Segment (%), FY2020
- Daiichi Sankyo Company Ltd. Sales Revenue Split, By Geography Segment (%), FY2020
- Eisai Co. Ltd. Revenue, 2019-2020 (In USD Billion)
- Eisai Co. Ltd. Revenue by Reporting Segment, FY2020
- Product Pipeline of Leading Alzheimer’s Drugs Companies
Companies Mentioned
- AbbVie Inc.
- F. Hoffman-La Roche Ltd.
- Novartis AG
- Biogen
- Pfizer Inc.
- Eli Lilli and Company
- Takeda Pharmaceutical Company Limited
- Novo Nordisk
- Daiichi Sankyo Company Ltd.
- Eisai Co. Ltd
- NervGen Pharma.
